---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000020"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:13:50.059600+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere's FILSPARI gets standard EU marketing authorization; receives $17.5M milestone

## Summary
- European Commission converts conditional approval to standard MA for FILSPARI (sparsentan) for primary IgAN in all EU member states, plus Iceland, Liechtenstein, Norway.
- UK MHRA also converted to standard approval on April 15, 2025.
- Company receives $17.5M milestone payment from CSL Vifor; eligible for additional market access and sales-based milestones.
- Approval based on Phase 3 PROTECT Study showing significant slowing of kidney function decline vs. irbesartan.

## SEC filing metadata
- accession: 0001438533-25-000020
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000020/0001438533-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000020/tvtx-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000020
- JSON: https://secwatch.observer/filing/0001438533-25-000020.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.